RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating

Group 1 - Apogee Therapeutics Inc. (NASDAQ:APGE) is considered a strong buy stock by Wall Street, with RBC Capital initiating coverage with an Outperform rating and a $60 price target [1] - The company is recognized for its potential to deliver clinically differentiated biologics, particularly in the treatment of atopic dermatitis, supported by early clinical data and recent Phase II results for its product APG777 [2][3] - RBC Capital highlights significant revenue opportunities for Apogee across various inflammation and immunology indications, reinforcing the positive outlook for the company [3] Group 2 - Apogee Therapeutics focuses on treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and related inflammatory and immunology conditions [3]